Product Description
KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy. (Sourced from: https://clinicaltrials.gov/study/NCT06223646)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Keyi (Zhejiang) Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Multiple Myeloma
Phase 1: POEMS Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KQ-2003-BC101 | P1 |
Not yet recruiting |
POEMS Syndrome |
2027-12-31 |
|
| KQ-2003-AC101 | P2 |
Recruiting |
Multiple Myeloma |
2026-03-31 |